11 research outputs found
Patterns and predictors of smoking by race and medical diagnosis during hospital admission: A latent class analysis
Hospital-based tobacco treatment programs provide tobacco cessation for a diverse array of admitted patients. Person-centered approaches to classifying subgroups of individuals within large datasets are useful for evaluating the characteristics of the sample. This study categorized patients who received tobacco treatment while hospitalized and determined whether demographics and smoking-related health conditions were associated with group membership. Chart review data was obtained from 4854 patients admitted to a large hospital in South Carolina, USA, from July 2014 through December 2019 who completed a tobacco treatment visit. Smoking characteristics obtained from the visit interview were dichotomized, and then latent class analysis (LCA) was conducted to categorize patients based on smoking history and interest in stopping smoking. Finally, logistic regressions were used to evaluate demographics and smoking-related health conditions as predictors of class membership. LCA generated 5 classes of patients, differentiated by heaviness of smoking and motivation to quit. Patients who were black/African American were more likely to be lighter smokers compared to white patients. Hospitalized patients with a history of hypertension, diabetes, and congestive heart failure were more likely to be motivated to quit and also were more likely to be lighter smokers at the time of hospitalization. Hospitalized patients who smoke and receive tobacco treatment are heterogeneous in terms of their smoking histories and motivation to quit. Understanding latent categories of patients provides insight for tailoring interventions and potentially improving tobacco treatment outcomes
The Yale Craving Scale: Development and psychometric properties
Introduction: The current study presents a psychometric evaluation of the Yale Craving Scale (YCS), a novel measure of craving for cigarettes and alcohol, respectively. The YCS is the first craving measure to use a generalized Labeled Magnitude Scale (gLMS) as the scoring format, which facilitates between-group comparisons of subjective craving and eliminates ceiling effects by assessing the full range of imaginable sensation intensities.
Methods: Psychometric evaluations of the YCS for use with cigarettes (YCS Smoking) and alcohol (YCS Drinking) included assessments of latent factor structure, internal consistency, ceiling effects, and test-criterion relationships. Study samples included 493 treatment-seeking smokers and 213 heavy drinkers.
Results: Factor analyses of the 5-item YCS Smoking and Drinking scores confirmed a 1-factor scale. The YCS Smoking and Drinking scores evidenced: (1) good internal consistency, (2) scalar measurement invariance within several subgroups (e.g., smoking/drinking status; nicotine/alcohol dependence), (3) convergent relationships with extant craving measures, and (4) concurrent relationships with smoking/drinking outcomes.
Conclusions: These results suggest that the YCS represents a psychometrically sound scale for assessing smoking and drinking urges in dependent populations
A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer
Introduction: Physical activity (PA) is a potential therapy to improve quality of life in patients with advanced-stage lung cancer (LC), but no PA regimen has been shown to be beneficial, clinically practical, and sustainable. We sought to test the hypothesis that a patient-centered activity regimen (PCAR) will improve patient participation and PA more effectively than weekly phone calls. Methods: In patients with advanced-stage LC, we implemented a walking-based activity regimen and motivated patients via either weekly phone calls (n = 29; FitBit Zip accelerometer) or PCAR (n = 15; FitBit Flex, an educational session, and twice-daily gain-framed text messages). Data collection over a 4-week period was compared, and a repeated-measures, mixed-effects model for activity level was constructed. Results: Subjects receiving PCAR more frequently used the device (100% vs 79%) and less frequently had missing data (11% vs 38%). “More active” and “less active” groups were created based on mean step count in the first week. “Less active” patients in the PCAR group increased their PA level, whereas PA level fell in the “more active” group. Most subjects found PCAR helpful (92%) and would participate in another activity study (85%). Discussion: Compared with weekly phone calls, PCAR has higher patient participation, is more likely to improve PA in “less active” subjects, and has high patient satisfaction. A multifaceted PA regimen may be a more efficacious mechanism to study PA in advanced LC. PCAR should be used in a randomized controlled trial to evaluate for improvements in symptom burden, quality of life, and mood
Recommended from our members
Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder
The introduction of alternative nicotine and tobacco products (such as e-cigarettes, heat-not-burn devices, nicotine pouches) warrants an updated framework from which to conceptualize tobacco use disorder (TUD). The following review provides considerations for TUD within the context of novel products. Historically, the tobacco industry falsely claimed that cigarettes were not addictive or harmful and that those who smoked simply chose to do so. This generated an inaccurate lay perception that smoking is a free or informed choice. Research on nicotine pharmacology demonstrates the powerful addictive potential of nicotine, which is shaped by dose, speed of delivery, and other constituents generated. In addition, non-pharmacologic reinforcers motivate and maintain tobacco use behaviors for both traditional cigarettes and novel products. The negative consequences of combustible tobacco use are well known; however, these outcomes may differ for alternative products. Strategies used for combustible product cessation may be adapted for novel products, and treatment recommendations for TUD should be made within the context of a harm reduction framework wherein alternative product use may be the desired outcome. Providers must therefore be willing to modify their perceptions of products and treatment recommendations accordingly. Better public health outcomes are accomplished through promotion of abstinence from combustible smoking. For those who cannot wean from nicotine entirely, switching to less risky modes of delivery might be a secondary goal, with an eventual aim of stopping use of the alternative product. Implications: Given the advent of novel, alternative tobacco products, tobacco use disorder (TUD) must be conceptualized within a contemporary framework that includes harm reduction and alternative outcomes. The unique contributions of nicotine pharmacology, non-pharmacologic reinforcers, and consequences of use can be used to inform treatments for TUD with the ultimate goal of improving the health of individuals who use tobacco